Navamedic (LSE:0FDB) - Stock Price, News & Analysis

0FDB Stock Overview

A pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally.

About the company

0FDB fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 85.1% below our estimate of its fair value

Earnings are forecast to grow 30.22% per year

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap (NOK427M)

Large one-off items impacting financial results

Profit margins (3.7%) are lower than last year (6.1%)

Navamedic ASA Competitors

ECO Animal Health Group

AIM:EAH

UK£49.1m

Animalcare Group

AIM:ANCR

UK£141.9m

Hikma Pharmaceuticals

LSE:HIK

UK£4.1b

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Price History & Performance

Summary of all time highs, changes and price drops for Navamedic
Historical stock prices
Current Share Price	NOK 30.70
52 Week High	NOK 36.50
52 Week Low	NOK 30.70
Beta	0.43
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	-17.47%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	391.20%

Recent updates

Shareholder Returns

	0FDB	GB Pharmaceuticals	GB Market
7D	0%	-8.9%	0.4%
1Y	-17.5%	-5.4%	7.6%

Return vs Industry: 0FDB underperformed the UK Pharmaceuticals industry which returned -5.4% over the past year.

Return vs Market: 0FDB underperformed the UK Market which returned 7.6% over the past year.

Price Volatility

Is 0FDB's price volatile compared to industry and market?
0FDB volatility
0FDB Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.9%
10% least volatile stocks in GB Market	2.5%

Stable Share Price: 0FDB's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0FDB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	45	Kathrine E. Andreassen	navamedic.com

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet.

Navamedic ASA Fundamentals Summary

How do Navamedic's earnings and revenue compare to its market cap?
0FDB fundamental statistics
Market cap	NOK 427.44m
Earnings (TTM)	NOK 19.62m
Revenue (TTM)	NOK 525.55m

21.8x

P/E Ratio

0.8x

P/S Ratio

Is 0FDB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0FDB income statement (TTM)
Revenue	NOK 525.55m
Cost of Revenue	NOK 315.24m
Gross Profit	NOK 210.31m
Other Expenses	NOK 190.69m
Earnings	NOK 19.62m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.11
Gross Margin	40.02%
Net Profit Margin	3.73%
Debt/Equity Ratio	46.0%

How did 0FDB perform over the long term?

See historical performance and comparison

Navamedic LSE:0FDB Stock Report